Chen, X., Song, X., Li, K. & Zhang, T. FcgammaR-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy. Front. Immunol. 10, 292 (2019).
Google Scholar
Whiteside, T. L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 16, 3–15 (2006).
Google Scholar
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Google Scholar
Syn, N. L., Teng, M. W. L., Mok, T. S. K. & Soo, R. A. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 18, e731–e741 (2017).
Google Scholar
Qin, S. et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer 18, 155 (2019).
Google Scholar
Dolladille, C. et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.0726 (2020).
Horvat, T. Z. et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J. Clin. Oncol. 33, 3193–3198 (2015).
Google Scholar
Zheng, N. & Shabek, N. Ubiquitin ligases: structure, function, and regulation. Annu. Rev. Biochem. 86, 129–157 (2017).
Google Scholar
Zeng, P., Ma, J., Yang, R. & Liu, Y.-C. In Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity. Current Topics in Microbiology and Immunology, Vol. 410, Ch. 64 (ed Yoshimura, A.) 215–248 (Springer, Cham, 2017).
Fujita, Y., Tinoco, R., Li, Y., Senft, D. & Ronai, Z. E. A. Ubiquitin ligases in cancer immunotherapy—balancing antitumor and autoimmunity. Trends Mol. Med. 25, 428–443 (2019).
Google Scholar
Mevissen, T. E. T. & Komander, D. Mechanisms of deubiquitinase specificity and regulation. Annu. Rev. Biochem. 86, 159–192 (2017).
Google Scholar
Foot, N., Henshall, T. & Kumar, S. Ubiquitination and the regulation of membrane proteins. Physiol. Rev. 97, 253–281 (2017).
Google Scholar
Liu, J., Qian, C. & Cao, X. Post-translational modification control of innate. Immunity 45, 15–30 (2016).
Google Scholar
Jiang, X. & Chen, Z. J. The role of ubiquitylation in immune defence and pathogen evasion. Nat. Rev. Immunol. 12, 35–48 (2011).
Google Scholar
Hu, H. & Sun, S. C. Ubiquitin signaling in immune responses. Cell Res. 26, 457–483 (2016).
Google Scholar
Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767–1778 (2016).
Google Scholar
Dyck, L. & Mills, K. H. G. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur. J. Immunol. 47, 765–779 (2017).
Google Scholar
Lim, S. et al. Interplay between immune checkpoint proteins and cellular metabolism. Cancer Res. 77, 1245–1249 (2017).
Google Scholar
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
Google Scholar
Sitaram, P., Uyemura, B., Malarkannan, S. & Riese, M. J. Beyond the cell surface: targeting intracellular negative regulators to enhance T cell anti-tumor activity. Int. J. Mol. Sci. 20, https://doi.org/10.3390/ijms20235821 (2019).
Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 20, 1239–1251 (2019).
Google Scholar
Ribas, A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315, 1600–1609 (2016).
Google Scholar
Hodi, F. S. et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 19, 1480–1492 (2018).
Google Scholar
Brahmer, J. R. et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 18, 1600–1609 (2017).
Google Scholar
Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
Google Scholar
Ye, M. et al. Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer. Cancer Res. 77, 3527–3539 (2017).
Google Scholar
Zhang, Y. et al. FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein. Cancer Lett. 419, 75–83 (2018).
Google Scholar
Chan, C. H. et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 154, 556–568 (2013).
Google Scholar
Yang, W. L. et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325, 1134–1138 (2009).
Google Scholar
Spain, L., Diem, S. & Larkin, J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat. Rev. 44, 51–60 (2016).
Google Scholar
Zeng, P., Ma, J., Yang, R. & Liu, Y. C. Immune regulation by ubiquitin tagging as checkpoint code. Curr. Top. Microbiol Immunol. 410, 215–248 (2017).
Google Scholar
Berndsen, C. E. & Wolberger, C. New insights into ubiquitin E3 ligase mechanism. Nat. Struct. Mol. Biol. 21, 301–307 (2014).
Google Scholar
Iwai, K., Fujita, H. & Sasaki, Y. Linear ubiquitin chains: NF-κB signalling, cell death and beyond. Nat. Rev. Mol. Cell Biol. 15, 503–508 (2014).
Google Scholar
Mansour, M. A. Ubiquitination: friend and foe in cancer. Int. J. Biochem. Cell Biol. 101, 80–93 (2018).
Google Scholar
Caulfield, T. R., Fiesel, F. C. & Springer, W. Activation of the E3 ubiquitin ligase Parkin. Biochem. Soc. Trans. 43, 269–274 (2015).
Google Scholar
Ohtake, F. et al. Ubiquitin acetylation inhibits polyubiquitin chain elongation. EMBO Rep. 16, 192–201 (2015).
Google Scholar
Micel, L. N., Tentler, J. J., Smith, P. G. & Eckhardt, G. S. Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J. Clin. Oncol. 31, 1231–1238 (2013).
Google Scholar
Gopinath, P., Ohayon, S., Nawatha, M. & Brik, A. Chemical and semisynthetic approaches to study and target deubiquitinases. Chem. Soc. Rev. 45, 4171–4198 (2016).
Google Scholar
Keane, M. M, Rivero-Lezcano, O. M., Mitchell, J. A., Robbins, K. C., & Lipkowitz, S. Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene. Oncogene 10, 2367–2377 (1995).
Kim, M. et al. Molecular cloning and characterization of a novel cbl-family gene, cbl-c. Gene 239, 145–154 (1999).
Google Scholar
Nau, M. M. & Lipkowitz, S. Comparative genomic organization of the cbl genes. Gene 308, 103–113 (2003).
Google Scholar
Lyle, C. et al. c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. Sci. Rep. 9, 20257 (2019).
Google Scholar
Wang, S. et al. E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer. FEBS Lett. 592, 621–630 (2018).
Google Scholar
Skaar, J. R., Pagan, J. K. & Pagano, M. SCF ubiquitin ligase-targeted therapies. Nat. Rev. Drug Discov. 13, 889–903 (2014).
Google Scholar
Welcker, M. & Clurman, B. E. FBW7 ubiquitin ligase—a tumour suppressor at the crossroads of Cell division, growth and differentiation. Nat. Rev. Cancer 8, 83–93 (2008).
Zheng, N. et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416, 703–709 (2002).
Google Scholar
Meng, X. et al. FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells. Nature 564, 130–135 (2018).
Google Scholar
Wertz, I. E. et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471, 110–114 (2011).
Google Scholar
Inuzuka, H. et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471, 104–109 (2011).
Google Scholar
Gstalder, C. et al. Inactivation of Fbxw7 impairs dsRNA sensing and confers resistance to PD-1 blockade. Cancer Disco. 10, 1296–1311 (2020).
Google Scholar
Cohen, P. & Frame, S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2, 769–776 (2001).
Google Scholar
Li, C. W. et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun. 7, 12632 (2016).
Google Scholar
Lim, S. O. et al. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell 30, 925–939 (2016).
Google Scholar
Zhang, M. et al. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1. Cell Prolif. 53, e12855, (2020).
Jingjing, W. et al. Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma. Cancer Med. 7, 4004–4011 (2018).
Google Scholar
Huang, X. et al. USP22 deubiquitinates CD274 to suppress anticancer immunity. Cancer Immunol. Res. 7, 1580–1590 (2019).
Google Scholar
Mao, R. et al. UCHL1 promotes expression of PD-L1 in non-small cell lung cancer cells. Cancer Sci. https://doi.org/10.1111/cas.14529 (2020).
Burr, M. L. et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 549, 101–105 (2017).
Google Scholar
Mezzadra, R. et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549, 106–110 (2017).
Google Scholar
Horita, H., Law, A., Hong, S. & Middleton, K. Identifying regulatory posttranslational modifications of PD-L1: a focus on monoubiquitinaton. Neoplasia 19, 346–353 (2017).
Google Scholar
Zhang, J. et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553, 91–95 (2018).
Google Scholar
Bhatia, S., Edidin, M., Almo, S. C. & Nathenson, S. G. B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties. Immunol. Lett. 104, 70–75 (2006).
Google Scholar
Lu, P., Wang, Y. L. & Linsley, P. S. Regulation of self-tolerance by CD80/CD86 interactions. Curr. Opin. Immunol. 9, 858–862 (1997).
Google Scholar
Anandasabapathy, N. et al. Grail. Immunity 18, 535–547 (2003).
Google Scholar
Stempin, C. C., Rojas Marquez, J. D., Ana, Y. & Cerban, F. M. GRAIL and Otubain-1 arerelated to T cell hyporesponsiveness during trypanosoma cruzi infection. PLoS Negl. Trop. Dis. 11, e0005307 (2017).
Google Scholar
Gibson, H. M. et al. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sezary syndrome. J. Invest. Dermatol. 133, 249–257 (2013).
Google Scholar
Mansouri, M. et al. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi’s sarcoma-associated herpesvirus. J. Virol. 83, 9672–9681 (2009).
Google Scholar
Coscoy, L., Sanchez, D. J. & Ganem, D. A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. J. Cell Biol. 155, 1265–1273 (2001).
Google Scholar
Lehner, P. J., Hoer, S., Dodd, R. & Duncan, L. M. Downregulation of cell surface receptors by the K3 family of viral and cellular ubiquitin E3 ligases. Immunol. Rev. 207, 112–125 (2005).
Google Scholar
Kajikawa, M. et al. The intertransmembrane region of Kaposi’s sarcoma-associated herpesvirus modulator of immune recognition 2 contributes to B7-2 downregulation. J. Virol. 86, 5288–5296 (2012).
Google Scholar
Means, R. E., Lang, S. M. & Jung, J. U. The Kaposi’s sarcoma-associated herpesvirus K5 E3 ubiquitin ligase modulates targets by multiple molecular mechanisms. J. Virol. 81, 6573–6583 (2007).
Google Scholar
Coscoy, L. & Ganem, D. A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. J. Clin. Invest. 107, 1599–1606 (2001).
Google Scholar
Ishido, S. C. J. et al. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi’s sarcoma-associated herpesvirus K5 protein. Immunity 13, 365–374 (2000).
Google Scholar
Cadwell, K. & Coscoy, L. The specificities of Kaposi’s sarcoma-associated herpesvirus-encoded E3 ubiquitin ligases are determined by the positions of lysine or cysteine residues within the intracytoplasmic domains of their targets. J. Virol. 82, 4184–4189 (2008).
Google Scholar
Herr, R. A., Harris, J., Fang, S., Wang, X. & Hansen, T. H. Role of the RING-CH domain of viral ligase mK3 in ubiquitination of non-lysine and lysine MHC I residues. Traffic 10, 1301–1317 (2009).
Google Scholar
Cadwell, K. & Coscoy, L. Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase. Science 309, 127–130 (2005).
Google Scholar
Nathan, J. A. & Lehner, P. J. The trafficking and regulation of membrane receptors by the RING-CH ubiquitin E3 ligases. Exp. Cell Res. 315, 1593–1600 (2009).
Google Scholar
Toyomoto, M., Ishido, S., Miyasaka, N., Sugimoto, H. & Kohsaka, H. Anti-arthritic effect of E3 ubiquitin ligase, c-MIR, expression in the joints. Int. Immunol. 23, 177–183 (2011).
Google Scholar
Goto, E. et al. c-MIR, a human E3 ubiquitin ligase, is a functional homolog of herpesvirus proteins MIR1 and MIR2 and has similar activity. J. Biol. Chem. 278, 14657–14668 (2003).
Google Scholar
Ohmura-Hoshino, M. et al. Cutting edge: requirement of MARCH-I-mediated MHC II ubiquitination for the maintenance of conventional dendritic cells. J. Immunol. 183, 6893–6897 (2009).
Google Scholar
Jabbour, M., Campbell, E. M., Fares, H. & Lybarger, L. Discrete domains of MARCH1 mediate its localization, functional interactions, and posttranscriptional control of expression. J. Immunol. 183, 6500–6512 (2009).
Google Scholar
Bourgeois-Daigneault, M. C. & Thibodeau, J. Identification of a novel motif that affects the conformation and activity of the MARCH1 E3 ubiquitin ligase. J. Cell Sci. 126, 989–998 (2013).
Google Scholar
Chattopadhyay, G. & Shevach, E. M. Antigen-specific induced T regulatory cells impair dendritic cell function via an IL-10/MARCH1-dependent mechanism. J. Immunol. 191, 5875–5884 (2013).
Google Scholar
Thibodeau, J. et al. Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. Eur. J. Immunol. 38, 1225–1230 (2008).
Google Scholar
Mittal, S. K., Cho, K. J., Ishido, S. & Roche, P. A. Interleukin 10 (IL-10)-mediated Immunosuppression: march-i induction regulates antigen presentation by macrophages but not dendritic cells. J. Biol. Chem. 290, 27158–27167 (2015).
Google Scholar
Katayama, S. et al. Apple polyphenols suppress antigen presentation of ovalbumin by THP-1-derived dendritic cells. Food Chem. 138, 757–761 (2013).
Google Scholar
Tze, L. E. et al. CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation. J. Exp. Med. 208, 149–165 (2011).
Google Scholar
Lopez-Relano, J. et al. Monocyte-derived dendritic cells differentiated in the presence of lenalidomide display a semi-mature phenotype, enhanced phagocytic capacity, and Th1 polarization capability. Front. Immunol. 9, 1328 (2018).
Google Scholar
Bourgeois-Daigneault, M. C. & Thibodeau, J. Autoregulation of MARCH1 expression by dimerization and autoubiquitination. J. Immunol. 188, 4959–4970 (2012).
Google Scholar
Lei, L., Bandola-Simon, J. & Roche, P. A. Ubiquitin-conjugating enzyme E2 D1 (Ube2D1) mediates lysine-independent ubiquitination of the E3 ubiquitin ligase March-I. J. Biol. Chem. 293, 3904–3912 (2018).
Google Scholar
Oh, J. et al. MARCH1-mediated MHCII ubiquitination promotes dendritic cell selection of natural regulatory T cells. J. Exp. Med. 210, 1069–1077 (2013).
Google Scholar
Young, L. J. et al. Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nat. Immunol. 9, 1244–1252 (2008).
Google Scholar
Oh, J. et al. MARCH1 protects the lipid raft and tetraspanin web from MHCII proteotoxicity in dendritic cells. J. Cell Biol. 217, 1395–1410 (2018).
Google Scholar
Borges, T. J. et al. March1-dependent modulation of donor MHC II on CD103(+) dendritic cells mitigates alloimmunity. Nat. Commun. 9, 3482 (2018).
Google Scholar
Galbas, T., Steimle, V., Lapointe, R., Ishido, S. & Thibodeau, J. MARCH1 down-regulation in IL-10-activated B cells increases MHC class II expression. Cytokine 59, 27–30 (2012).
Google Scholar
Matsuki, Y. et al. Novel regulation of MHC class II function in B cells. EMBO J. 26, 846–854 (2007).
Google Scholar
Galbas, T. et al. MARCH1 E3 ubiquitin ligase dampens the innate inflammatory response by modulating monocyte functions in mice. J. Immunol. 198, 852–861 (2017).
Google Scholar
Ohmura-Hoshino, M. et al. Inhibition of MHC class II expression and immune responses by c-MIR. J. Immunol. 177, 341–354 (2006).
Google Scholar
Cho, K. J., Walseng, E., Ishido, S. & Roche, P. A. Ubiquitination by March-I prevents MHC class II recycling and promotes MHC class II turnover in antigen-presenting cells. Proc. Natl Acad. Sci. USA 112, 10449–10454 (2015).
Google Scholar
Hunt, D. et al. Francisella tularensis elicits IL-10 via a PGE(2)-inducible factor, to drive macrophage MARCH1 expression and class II down-regulation. PLoS ONE 7, e37330 (2012).
Google Scholar
Wilson, J. E., Katkere, B. & Drake, J. R. Francisella tularensis induces ubiquitin-dependent major histocompatibility complex class II degradation in activated macrophages. Infect. Immun. 77, 4953–4965 (2009).
Google Scholar
Bayer-Santos, E. et al. The Salmonella effector SteD mediates MARCH8-dependent ubiquitination of MHC II molecules and inhibits T cell activation. Cell Host Microbe 20, 584–595 (2016).
Google Scholar
von Rohrscheidt, J. et al. Thymic CD4 T cell selection requires attenuation of March8-mediated MHCII turnover in cortical epithelial cells through CD83. J. Exp. Med. 213, 1685–1694 (2016).
Google Scholar
Liu, H. et al. Ubiquitin ligase MARCH 8 cooperates with CD83 to control surface MHC II expression in thymic epithelium and CD4 T cell selection. J. Exp. Med. 213, 1695–1703 (2016).
Google Scholar
Gao, J., Zheng, Q., Xin, N., Wang, W. & Zhao, C. CD155, an onco-immunologic molecule in human tumors. Cancer Sci. 108, 1934–1938 (2017).
Google Scholar
Molfetta, R. et al. The Ubiquitin-proteasome pathway regulates Nectin2/CD112 expression and impairs NK cell recognition and killing. Eur. J. Immunol. 49, 873–883 (2019).
Google Scholar
van den Boomen, D. J. & Lehner, P. J. Identifying the ERAD ubiquitin E3 ligases for viral and cellular targeting of MHC class I. Mol. Immunol. 68, 106–111 (2015).
Google Scholar
Zitti, B. et al. Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells. Sci. Rep. 7, 10445 (2017).
Google Scholar
Nagata, S., Suzuki, J., Segawa, K. & Fujii, T. Exposure of phosphatidylserine on the cell surface. Cell Death Differ. 23, 952–961 (2016).
Google Scholar
Schumacher, M. M., Choi, J.-Y. & Voelker, D. R. Phosphatidylserine transport to the mitochondria is regulated by ubiquitination. J. Biol. Chem. 277, 51033–51042 (2002).
Google Scholar
Campbell, K. S. & Purdy, A. K. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 132, 315–325 (2011).
Google Scholar
Bartee, E., Mansouri, M., Hovey Nerenberg, B. T., Gouveia, K. & Fruh, K. Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins. J. Virol. 78, 1109-1120 (2004).
Tan, C., Byrne, E. F. X., Ah-Cann, C., Call, M. J. & Call, M. E. A serine in the first transmembrane domain of the human E3 ubiquitin ligase MARCH9 is critical for down-regulation of its protein substrates. J. Biol. Chem. 294, 2470–2485 (2019).
Google Scholar
Fruh, K., Bartee, E., Gouveia, K. & Mansouri, M. Immune evasion by a novel family of viral PHD/LAP-finger proteins of gamma-2 herpesviruses and poxviruses. Virus Res. 88, 55–69 (2002).
Google Scholar
Ishido, S., Wang, C., Lee, B. S., Cohen, G. B. & Jung, J. U. Downregulation of major histocompatibility complex class I molecules by Kaposi’s sarcoma-associated herpesvirus K3 and K5 proteins. J. Virol. 74, 5300–5309 (2000).
Google Scholar
Stevenson, P. G., Efstathiou, S., Doherty, P. C. & Lehner, P. J. Inhibition of MHC class I-restricted antigen presentation by gamma 2-herpesviruses. Proc. Natl Acad. Sci. USA 97, 8455–8460 (2000).
Google Scholar
Coscoy, L. & Ganem, D. Kaposi’s sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc. Natl Acad. Sci. USA 97, 8051–8056 (2000).
Google Scholar
Duncan, L. M. et al. Lysine-63-linked ubiquitination is required for endolysosomal degradation of class I molecules. EMBO J. 25, 1635–1645 (2006).
Google Scholar
De Angelis Rigotti, F. et al. MARCH9-mediated ubiquitination regulates MHC I export from the TGN. Immunol. Cell Biol. 95, 753–764 (2017).
Google Scholar
Wang, X., Connors, R., Harris, M. R., Hansen, T. H. & Lybarger, L. Requirements for the selective degradation of endoplasmic reticulum-resident major histocompatibility complex class I proteins by the viral immune evasion molecule mK3. J. Virol. 79, 4099–4108 (2005).
Google Scholar
Wang, X., Lybarger, L., Connors, R., Harris, M. R. & Hansen, T. H. Model for the interaction of gammaherpesvirus 68 RING-CH finger protein mK3 with major histocompatibility complex class I and the peptide-loading complex. J. Virol. 78, 8673–8686 (2004).
Google Scholar
Stagg, H. R. et al. The TRC8 E3 ligase ubiquitinates MHC class I molecules before dislocation from the ER. J. Cell Biol. 186, 685–692 (2009).
Google Scholar
Sica, G. L. et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18, 849–861 (2003).
Google Scholar
Podojil, J. R. & Miller, S. D. Potential targeting of B7-H4 for the treatment of cancer. Immunol. Rev. 276, 40–51 (2017).
Google Scholar
Song, X. et al. Pharmacological suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-20-0402 (2020).
Manasanch, E. E. & Orlowski, R. Z. Proteasome inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 14, 417–433 (2017).
Google Scholar
Yao, H. et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat. Biomed. Eng. 3, 306–317 (2019).
Google Scholar
Naujokat, C. et al. Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells. Immunology 120, 120–132 (2007).
Google Scholar
Deng, L., Meng, T., Chen, L., Wei, W. & Wang, P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Sig. Transduct. Targeted Ther. 5, https://doi.org/10.1038/s41392-020-0107-0 (2020).
Ceccarelli, D. F. et al. An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell 145, 1075–1087 (2011).
Google Scholar
Deng, L. et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351–361 (2000).
Google Scholar
Pulvino, M. et al. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood 120, 1668–1677 (2012).
Google Scholar
Ren, Y. et al. Novel immunomodulatory properties of berbamine through selective down-regulation of STAT4 and action of IFN-gamma in experimental autoimmune encephalomyelitis. J. Immunol. 181, 1491–1498 (2008).
Google Scholar
Chauhan, D. et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22, 345–358 (2012).
Google Scholar
Sakamoto, K. M. K. K., Kumagai, A., Mercurio, F., Crews, C. M. & Deshaies, R. J. Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554–8559 (2001).
Google Scholar
Reynders, M. et al. PHOTACs enable optical control of protein degradation. Sci. Adv. 6, eaay5064 (2020).
Google Scholar
Liu, J. et al. Light-induced control of protein destruction by opto-PROTAC. Sci. Adv. 6, eaay5154 (2020).
Google Scholar
Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).
Google Scholar
Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459–465 (1995).
Google Scholar
Topalian, S. L., Drake, C. G. & Pardoll, D. M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24, 207–212 (2012).
Google Scholar
Baixeras, E. et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J. Exp. Med. 176, 327–337 (1992).
Google Scholar
Wang, J. et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell 176, 334–347 (2019). e312.
Google Scholar
Yu, X. et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10, 48–57 (2009).
Google Scholar
Anderson, A. C., Joller, N. & Kuchroo, V. K. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44, 989–1004 (2016).
Google Scholar
Andrews, L. P., Yano, H. & Vignali, D. A. A. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat. Immunol. 20, 1425–1434 (2019).
Google Scholar
Freeman, G. J., Casasnovas, J. M., Umetsu, D. T. & DeKruyff, R. H. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol. Rev. 235, 172–189 (2010).
Google Scholar
Hobo, W. et al. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation. J. Immunol. 189, 39–49 (2012).
Google Scholar
Han, P., Goularte, O. D., Rufner, K., Wilkinson, B. & Kaye, J. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J. Immunol. 172, 5931–5939 (2004).
Google Scholar
Wang, L. et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577–592 (2011).
Google Scholar
Castellanos, J. R. et al. B7-H3 role in the immune landscape of cancer. Am. J. Clin. Exp. Immunol. 6, 66–75 (2017).
Google Scholar
Flem-Karlsen, K., Fodstad, Y. & Nunes-Xavier, C. E. B7-H3 immune checkpoint protein in human cancer. Curr. Med. Chem. https://doi.org/10.2174/0929867326666190517115515 (2019).
He, L. & Li, Z. B7-H3 and its role in bone cancers. Pathol. Res Pr. 215, 152420 (2019).
Google Scholar
Husain, B. et al. A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7-H3/CD276 and PVR/CD155. Mol. Cell Proteom. 18, 2310–2323 (2019).
Google Scholar
Sica, G. L. et al. B7-H4, a molecule of the B7 family, negatively regulates T cell. Immunity 18, 849–861 (2003).
Google Scholar
Wang, J.-Y. & Wang, W.-P. B7-H4, a promising target for immunotherapy. Cell. Immunol. 347, https://doi.org/10.1016/j.cellimm.2019.104008 (2020).
Pende, D. et al. Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation. Front. Immunol. 10, 1179 (2019).
Google Scholar
Liu, W. et al. Structural basis of CD160:HVEM recognition. Structure 27, 1286–1295.e1284 (2019).
Google Scholar
Allard, B., Longhi, M. S., Robson, S. C. & Stagg, J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol. Rev. 276, 121–144 (2017).
Google Scholar
Ghalamfarsa, G. et al. CD73 as a potential opportunity for cancer immunotherapy. Expert Opin. Ther. Targets 23, 127–142 (2019).
Google Scholar
Dougall, W. C., Kurtulus, S., Smyth, M. J. & Anderson, A. C. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol. Rev. 276, 112–120 (2017).
Google Scholar
Georgiev, H., Ravens, I., Papadogianni, G. & Bernhardt, G. Coming of age: CD96 emerges as modulator of immune responses. Front Immunol. 9, 1072 (2018).
Google Scholar
Cheng, J. et al. Functional analysis of deubiquitylating enzymes in tumorigenesis and development. Biochim. Biophys. Acta Rev. Cancer 1872, 188312 (2019).
Google Scholar
Mennerich, D., Kubaichuk, K. & Kietzmann, T. DUBs, hypoxia, and cancer. Trends Cancer 5, 632–653 (2019).
Google Scholar
